Levetiracetam as the First-line Antiepileptic in Neonatal Seizures

Document Type : Original Article

Authors

Pediatrics Department, Kasturba Medical College, Manipal Academy of Higher Education(MAHE), Manipal, Karnataka, India

Abstract

Background: The quest persists for an ideal newer antiepileptic drug (AED) with better efficacy and tolerability. Levetiracetam (LEV) is one of these AEDs with a novel mechanism of action, good pharmacokinetic profile, acceptable tolerability, and side-effect profile. The present study assessed the safety and efficacy of intravenous levetiracetam as a first-line AED in neonatal seizures.
Methods: This prospective observational study was conducted on all term neonates with seizures admitted to the Neonatal Intensive Care Unit (NICU) of a tertiary care center. Neonates with hypoglycemia, hypocalcemia, hypomagnesemia, inborn errors of metabolism, or those who received other AEDs prior to admission were excluded from the study. 20mg/kg Intravenous LEV was administered as first-line AED and graded up to 40mg/kg if seizures were not controlled in 2 h; thereafter, second-line AED was added.
Results: Only 36.2% (21/58) of the cases responded to LEV as first-line AED. Hypoxic Ischaemic Encephalopathy(HIE) was the most common etiology of seizures (55.2%). Subtle seizures were most responsive to LEV (60%), while multifocal clonic seizures (22.3%) responded the least. No adverse effect of LEV was observed during the study period.
Conclusion: Only 36.2% of the cases responded to LEV as first-line AED, and subtle seizures were the most responsive seizures. Therefore, the efficacy of LEV as first-line AED in neonatal seizures is yet to be proven by a larger study. There were no adverse effects of LEV during the study period indicating the relative safety of this drug.

Keywords

References

1. Volpe JJ. Neonatal seizures. Neurology of the new-born. 5th ed. Philadelphia: W.B Saunders; 2008. P. 203-44.
2. Holmes GL, Ben-Ari Y. The neurobiology and consequences of epilepsy in the developing brain. Pediatr Res. 2001; 49(3):320-5.
3. Thibeault-Eybalin MP, Lortie A, Carmant L. Neonatal seizures: do they damage the brain? Paediatr Neurol. 2009; 40(3):175-80.
4. Holmes GL. The long term effects of neonatal seizures. Clin Perinatol. 2009; 36(4):901-14.
5. Booth D, Evans DJ. Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev. 2004; 4:CD004218.
6. Bittigau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci. 2003; 993:103-14.
7. Silverstein FS, Ferriero DM. Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol. 2008; 39(2):77-9.
8. Mruk LA, Garlitz KL, Leung RN. Levetiracetam in neonatal seizures: review. J Pediatr Pharmacol Ther. 2015; 20(2):76-89.
9. Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: safety and efficacy in neonatal seizures. Eur J Paediatr Neurol. 2011;
15(1):1-7.
10. Sedighi M, Asadi F, Moradian N, Vakiliamini M, Moradian M. Efficacy and safety of levetiracetam in the management of seizures in neonates. Neurosciences. 2016; 21(3):232-2.
11. Khan O, Chang E, Cipriani C, Wright C, Crisp E, Kumani B. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol. 2011; 44(4):265-9.
12. Malik BA, Butt MS, Sharmoon M, Tehseen Z, Fatima A, Hashmat N. Seizure etiology in the newborn period. J Coll Physicians Surg Pak. 2005; 15(12): 786-90.
13. Alcover-Bloch E, Camistol J, Iriondo-Sanz M. Neonatal seizures, our experience. Rev Neurol. 2004; 38(9):808-12.
14. World Health Organization. Guidelines on neonatal seizures. Geneva: World Health Organization; 2011.
15. Rollins NK, Morris MC, Evans D, Perlman JM. The role of early MR in evaluation of the term infant with seizures. AJNR Am J Neuroradiol. 1994; 15(2):239-48.
16. Miller SP, Weiss J, Barnwell A, Ferriero DM, Latal Hajnal B, Ferrer Rogers A, et al. Seizure associated brain injury in term newborns with perinatal asphyxia. Neurology. 2002; 58(4):542-8.
17. Scarpa P, Chierici R, Tamisari L, Fortini C, Volpato S. Criteria for discontinuing neonatal seizure therapy: a long term appraisal. Brain Dev. 1983; 5(6):541-8.
18. Bye AM, Flanagan D. Spatial and temporal characteritics of neonatal seizures. Epilepsia. 1995; 36(10):1009-16.
19. Connell J, Oozeer R, Vries LD, Dubowitz LM, Dubowitz V. Clinical and EEG response to anticonvulsants in neonatal seizures. Arch Dis Child.1989; 64(4):459-64.
20. Falsaperla R, Vitaliti G, Mauceri L, Romano C, Pavone P, Motamed-Gorji N, et al. Levetiracetam in neonatal seizures as first line treatment: a prospective study. J Pediatr Neurosci. 2017; 12(1):24-8.
21. Abend NS, Gutierrez-Colina AM, Monk HM, Dlugos DJ, Claney RR. Levetiracetam for treatment of neonatal seizures. J Child Neurol. 2011; 26(4): 465-70.
Iranian Journal of Neonatology
Volume 11, Issue 4
October 2020
Pages 39-45

Files

Share

How to cite

Statistics